In nasopharyngeal cancer, Chen et al. [13] showed that increased TBL1XR1 expression suppressed cisplatin-induced apoptosis and may serve as an effective biomarker for selective therapeutic regimen for NPC patients. Here, TBL1XR1 is linked to nasopharyngeal carcinoma.